The prognostic value of thymidylate synthase and p53 expression in patients treated with induction chemotherapy for squamous cell carcinoma of the head and neck

Oncologist

Volumn 3, Issue 6, 1998, Pages 424-431

  Posner, Marshall R ^a   Johnston, Patrick G ^c   Tishler, Roy B ^a,b   Andersen, Janet ^a   Fiorentino, Michelangelo ^a   Busse, Paul M ^a,b   Cavacini, Lisa A ^a   Dimitrios Colevas, A ^a   Clark, John ^b   Norris, Charles M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

5 Fluorouracil; Cisplatin; Immunohistochemistry

Indexed keywords

CISPLATIN; FLUOROURACIL; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EID: 0032445561     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-6-424     Document Type: Article

References (18)

1. Merlano M, Benasso M, Corvo R et al. Five year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996;88:583-589.
2. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del collo. J Natl Cancer Inst 1994;86:265-272.
3. Browman G, Cripps C, Hudson D et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 1994;12:2648-2653.
4. Lefebvre J, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organisation for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996;88:890-898.
5. Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-1689.
6. Pinedo H, Peters G. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988;6:1653-1664.
7. Lenz H, Leichman C, Danenberg K et al. Thymidylate synthase mRNA levels in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-182.
8. Leichman C, Lentz H, Leichman L et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-3229.
9. Lenz H, Hayashi K, Salonga D et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal carcinoma: an analysis of response and survival. Clin Cancer Res 1998;4:1243-1250.
10. Johnston P, Fisher E, Rockette H et al. The role of thymidylate synthase expression in the prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-2647.
11. Pestalozzi B, Peterson H, Gelber R et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997;15:1923-1931.
12. Johnston P, Mick R, Recant W et al. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 1997;89:308-313.
13. Harris C. Structure and function of the p53 tumor suppressor gene: clues for rational therapeutic cancer strategies. J Natl Cancer Inst 1996;88:1442-1455.
14. Lowe S, Ruley H, Jacks T et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.
15. Lowe S, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810.
16. Tishler R, Calderwood S, Coleman N et al. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 1993;53:2212-2216.
17. Rusch V, Klimstra D, Venkatraman E et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 1995;55:5038-5042.
18. Lee J, Yoon A, Kalapurakal S et al. Expression of p53 oncoprotein in non-small cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995;13:1893-1903.